Compare Stocks: YARW, IFRX, UPB, and IMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IFRX InflaRx	$1.82 -3.7%	$2.00	$0.80 ▼ $2.95	$278.53M	2.52	498,000 shs	426,387 shs
IMRX Immuneering	$4.16 -2.6%	$4.67	$3.86 ▼ $8.48	$276.26M	0.4	678,536 shs	597,905 shs
UPB Upstream Bio	$5.30 -1.1%	$6.36	$4.99 ▼ $33.68	$293.57M	1.28	592,111 shs	615,401 shs
YARW Yarrow Bioscience	$24.00 -6.0%	$33.87	$16.00 ▼ $46.95	$68.18M	2.01	165,651 shs	107,656 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IFRX InflaRx	0.00%	-9.79%	-15.25%	-17.11%	+45.38%
IMRX Immuneering	0.00%	-4.69%	-14.43%	-15.45%	-47.15%
UPB Upstream Bio	0.00%	+0.37%	-19.88%	-22.66%	-68.95%
YARW Yarrow Bioscience	0.00%	-12.80%	-30.97%	+2,553,999,900.00%	+2,553,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IFRX InflaRx	$1.82 -3.7%	$2.00	$0.80 ▼ $2.95	$278.53M	2.52	498,000 shs	426,387 shs
IMRX Immuneering	$4.16 -2.6%	$4.67	$3.86 ▼ $8.48	$276.26M	0.4	678,536 shs	597,905 shs
UPB Upstream Bio	$5.30 -1.1%	$6.36	$4.99 ▼ $33.68	$293.57M	1.28	592,111 shs	615,401 shs
YARW Yarrow Bioscience	$24.00 -6.0%	$33.87	$16.00 ▼ $46.95	$68.18M	2.01	165,651 shs	107,656 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IFRX InflaRx	0.00%	-9.79%	-15.25%	-17.11%	+45.38%
IMRX Immuneering	0.00%	-4.69%	-14.43%	-15.45%	-47.15%
UPB Upstream Bio	0.00%	+0.37%	-19.88%	-22.66%	-68.95%
YARW Yarrow Bioscience	0.00%	-12.80%	-30.97%	+2,553,999,900.00%	+2,553,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IFRX InflaRx	2.67	Moderate Buy	$7.43	308.16% Upside
IMRX Immuneering	3.00	Buy	$15.71	277.75% Upside
UPB Upstream Bio	2.43	Hold	$29.67	459.75% Upside
YARW Yarrow Bioscience	2.33	Hold	$58.00	141.67% Upside

Current Analyst Ratings Breakdown

Latest YARW, IFRX, UPB, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	IMRX Immuneering	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/27/2026	IMRX Immuneering	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/6/2026	IMRX Immuneering	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IFRX InflaRx	$30K	8,940.45	N/A	N/A	$0.65 per share	2.80
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
UPB Upstream Bio	$2.85M	101.85	N/A	N/A	$6.29 per share	0.84
YARW Yarrow Bioscience	$570K	112.42	N/A	N/A	$41.71 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	11/11/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest YARW, IFRX, UPB, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	YARW Yarrow Bioscience	-$0.18	-$3.51	-$3.33	-$3.51	$0.20 million	$0.10 million
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Latest YARW, IFRX, UPB, and IMRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	YARW Yarrow Bioscience	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IFRX InflaRx	N/A	8.22	8.22
IMRX Immuneering	N/A	19.47	19.47
UPB Upstream Bio	N/A	27.99	27.99
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IFRX InflaRx	42.39%
IMRX Immuneering	67.65%
UPB Upstream Bio	N/A
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
IFRX InflaRx	16.30%
IMRX Immuneering	14.90%
UPB Upstream Bio	16.46%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
IMRX Immuneering	57	64.70 million	55.06 million	Not Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

YARW, IFRX, UPB, and IMRX Headlines

Recent News About These Companies

Yarrow Bioscience (NASDAQ:YARW) Short Interest Update

September 28 at 10:41 AM | americanbankingnews.com

Yarrow Bioscience (NASDAQ:YARW) Sees Significant Increase in Short Interest

September 27 at 9:59 AM | marketbeat.com

Yarrow Bioscience Inc YARW

September 15, 2026 | morningstar.comM

Yarrow Bioscience Closes $172.5 Million Public Offering

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Underwritten Equity Offering Agreement

September 14, 2026 | tipranks.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

September 14, 2026 | businesswire.com

Yarrow Bioscience Details Pricing for $150 Million Public Offering of Common Stock

September 14, 2026 | mobile.visionmonday.comM

Yarrow Bioscience Stock Falls 7% On Pricing Of $150 Mln Public Offering

September 13, 2026 | rttnews.com

Short Interest in Yarrow Bioscience (NASDAQ:YARW) Rises By 190.8%

September 13, 2026 | marketbeat.com

Yarrow Bioscience prices $150M public offering of common stock at $26 per share

September 11, 2026 | msn.com

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

September 10, 2026 | businesswire.com

Yarrow Bioscience Launches Public Offering of Common Stock

September 10, 2026 | finance.yahoo.com

Yarrow Bioscience Updates Strategy for Thyroid Autoimmune Pipeline

September 10, 2026 | tipranks.com

Yarrow Bioscience Announces Proposed Underwritten Public Offering

September 10, 2026 | businesswire.com

BlackRock Inc. Takes Position in Yarrow Bioscience $YARW

September 10, 2026 | marketbeat.com

40,697 Shares in Yarrow Bioscience $YARW Purchased by Two Sigma Securities LLC

September 7, 2026 | marketbeat.com

Yarrow Bioscience’s YB-101 Trial Targets Graves’ Disease, Raising New Investor Interest

September 4, 2026 | tipranks.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IFRX, UPB, and IMRX Company Descriptions

InflaRx NASDAQ:IFRX

$1.82 -0.07 (-3.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.81 -0.01 (-0.55%)

As of 07:37 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Immuneering NASDAQ:IMRX

$4.16 -0.11 (-2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$4.16 0.00 (-0.12%)

As of 07:30 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Upstream Bio NASDAQ:UPB

$5.30 -0.06 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$5.30 0.00 (0.00%)

As of 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Yarrow Bioscience NASDAQ:YARW

$24.00 -1.54 (-6.03%)

Closing price 04:00 PM Eastern

Extended Trading

$23.98 -0.02 (-0.10%)

As of 07:30 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, IFRX, UPB, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, IFRX, UPB, and IMRX Earnings

Compare Dividends

Latest YARW, IFRX, UPB, and IMRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, IFRX, UPB, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IFRX, UPB, and IMRX Company Descriptions

InflaRx NASDAQ:IFRX

Immuneering NASDAQ:IMRX

Upstream Bio NASDAQ:UPB

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, IFRX, UPB, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, IFRX, UPB, and IMRX Earnings

Compare Dividends

Latest YARW, IFRX, UPB, and IMRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, IFRX, UPB, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IFRX, UPB, and IMRX Company Descriptions

InflaRx NASDAQ:IFRX

Immuneering NASDAQ:IMRX

Upstream Bio NASDAQ:UPB

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools